McKarney I
Issues Emerg Health Technol. 2007 Sep(101):1-4.
(1) Sipuleucel-T (Provenge) is an active cellular immunotherapy (therapeutic vaccine) that is designed to stimulate the patient's T-cells to recognize and attack prostate cancer cells that express prostatic acid phosphatase (PAP) antigen. (2) Sipuleucel-T demonstrated a survival benefit in men with advanced androgen-independent prostate cancer (AIPC), although this preliminary finding requires confirmation in larger trials. (3) Mild to moderate myalgia, chills, fever, and tremor are the most commonly reported adverse events for patients receiving sipuleucel-T. These events generally resolve quickly. (4) More studies are needed to evaluate sipuleucel-T in the earlier stages of prostate cancer and in combination with conventional therapies.
（1）西妥昔单抗（普罗文奇）是一种活性细胞免疫疗法（治疗性疫苗），旨在刺激患者的T细胞识别并攻击表达前列腺酸性磷酸酶（PAP）抗原的前列腺癌细胞。（2）西妥昔单抗在晚期雄激素非依赖性前列腺癌（AIPC）男性患者中显示出生存获益，尽管这一初步发现需要在更大规模的试验中得到证实。（3）轻度至中度肌痛、寒战、发热和震颤是接受西妥昔单抗治疗的患者最常报告的不良事件。这些事件通常会迅速缓解。（4）需要更多研究来评估西妥昔单抗在前列腺癌早期阶段以及与传统疗法联合使用时的效果。
